Compare Infosys Limited (INFY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Merck & Co., Inc. — how do they compare? Infosys Limited trades at $10.73 (market cap $41.74B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 8.4× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Merck & Co., Inc. for 98 Days on average.
| INFY | MRK | |
|---|---|---|
Market Cap | $41.74B | $351.28B |
Volume | 31,354,285 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $20.22 | $156.43 |
52-Week Low | $10.49 | $82.49 |
Typical Hold Time | 27 Days | 98 Days |
Enterprise Value | $39.48B | $398.04B |
Dividend Yield | 4.89% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.70, up 1.42% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025, with a net income margin of 16.37%. Recent news highlights strategic AI collaborations, including with Columbia University and ABN Amro. Analyst consensus is a 'Hold' with a $11.48 price target, indicating modest upside potential from current levels.
The outlook is mixed: strong profitability and recent earnings beats support the stock, but a projected negative net cash flow in 2026 and bearish technical indicators pose risks. Investor sentiment is cautious amid weak Western IT spending concerns, though institutional holdings show confidence. Key risks include competitive pressures and macroeconomic headwinds affecting IT services demand.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
